This catalog entry uses the labels AHK and Tripeptide-3. The essential first question is which ingredient the listing actually identifies. The reviewed hair-follicle experiment tested the copper complex AHK-Cu; it should not be used as a clinical result for plain AHK.
AHK-Cu is a copper complex of the tripeptide alanine–histidine–lysine. Its best-matched source in the reviewed record is a laboratory study of isolated human hair follicles and dermal papilla cells. Human-derived tissue is useful, but it is not evidence that a cosmetic or injectable product regrows hair in patients.
ARA-290 is an experimental peptide designed from erythropoietin for tissue-protective signaling without its red-blood-cell-stimulating action. Early clinical studies investigated neuropathic symptoms in specific patient groups. Their results are more informative than generic nerve-healing claims, but remain limited by size, duration and endpoint selection.
B7-33 is a synthetic peptide modeled on part of relaxin-2 and investigated for signaling through relaxin family peptide receptor 1. Selected animal and cell experiments report vascular and cardiac effects. They are a basis for further research, not proof of a human cardiovascular or antifibrotic treatment.
BPC-157 has been investigated in tissue-repair models and a limited human literature. Laboratory findings support further research, but they do not establish that a commercial preparation heals an injury, treats a gastrointestinal condition or is safe for routine use. The human reports ask different questions and should be examined separately.
Cardiogen is a named synthetic tetrapeptide studied in organotypic rat-heart cultures. These experiments examine tissue growth and molecular markers outside a living patient. They do not demonstrate treatment of heart failure, arrhythmia or a heart attack in people.
Cartalax is indexed by the US National Library of Medicine under alanyl–glutamyl–aspartic acid, also called AED or T-31. The directly identifiable primary studies reviewed here concern kidney cultures and rat kidney injury. They do not substantiate a claim that Cartalax rebuilds human cartilage.
Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain. Clinical research includes stroke rehabilitation, but results depend on the study and outcome. This evidence does not establish a general memory or focus enhancer for healthy people.
Chonluten is a named tripeptide investigated in laboratory models of inflammatory signaling. A directly relevant study used a human leukemia-derived cell line that can be differentiated into macrophage-like cells. It did not test a treatment in people with asthma, chronic obstructive pulmonary disease or another respiratory condition.
CJC-1295 was developed as a long-acting analogue of growth-hormone-releasing hormone. Early human studies demonstrated changes in growth hormone and IGF-1, not proven anti-aging, fat-loss or muscle-performance outcomes. Exact identity is essential because the CJC name is used inconsistently across product listings.
A CJC/ipamorelin blend combines substances investigated through different growth-hormone signaling pathways. A plausible combination mechanism is not a clinical trial of the blend. The first questions are which CJC-related molecule is present, what the individual amounts are, and whether the claimed outcome was actually measured for that combination.
CJC-1295 with DAC refers to the albumin-binding, long-acting research construct associated with the original CJC-1295 studies. Its prolonged hormone effects are experimentally documented. They should not be confused with demonstrated clinical benefits or transferred to a product lacking that modification.
Collagen peptides are mixtures produced by breaking down collagen proteins. Selected oral formulations have randomized human studies in skin, joint discomfort and bone density. The results belong to those preparations and outcomes; they do not show that every collagen product repairs injured tissue or prevents fractures.
Cortagen is the synthetic tetrapeptide Ala–Glu–Asp–Pro. Its research includes mouse gene-expression and behavioral experiments. These findings do not establish improved memory, nerve repair or treatment of depression in people, and the similarly named Cortexin is a different mixture.
Follistatin is a protein involved in signaling by members of the TGF-beta family. “Follistatin 344” appears in experimental gene-transfer literature, but that does not mean an injectable product sold with the same number reproduces the intervention. The distinction between a gene construct, its processed protein and a short inhibitory fragment is central to evaluating muscle-growth claims.
FOXO4-DRI is an experimental peptide associated with research on disrupting the FOXO4–p53 interaction in senescent cells. The influential primary study tested cellular mechanisms and mouse outcomes. It provides a research rationale for targeting some senescent cells, not proof that a commercial preparation reverses aging in people.
GHK-Cu is a copper complex of the tripeptide glycyl-histidyl-lysine. It is discussed in skin-care and tissue-repair research, but the route and formulation are essential to interpreting a claim. A skin product tested after a procedure is not evidence that injecting GHK-Cu improves skin, hair or whole-body repair.
Ghrelin is a hormone involved in appetite and growth-hormone signaling. Direct human experiments show that giving ghrelin can increase short-term food intake. That does not make it a proven long-term strategy for weight management, muscle gain or recovery from illness.
GHRP-2 is a synthetic growth-hormone secretagogue that acts in the ghrelin signaling system. Controlled human experiments demonstrate hormone and appetite responses. These responses are evidence of biological activity, but they are not the same as showing improved strength, recovery or body composition.
GHRP-6 is a synthetic peptide studied for its ability to stimulate growth-hormone secretion. A directly relevant human experiment compared hormone responses to GHRP-6, growth-hormone-releasing hormone and their combination. It did not test an anti-aging program, injury recovery or long-term muscle gain.
GLOW is a name used for combinations of peptides rather than one universally defined molecule. This guide concerns blends listing BPC-157, a thymosin-related ingredient and GHK-Cu. A useful assessment starts with the actual ingredient identities and amounts, because the label alone does not define a reproducible intervention.
Glutathione is a tripeptide involved in cellular redox biology. That biological role does not mean every supplement or infusion improves health. The important questions are what preparation was given, whether it changed a meaningful outcome, and whether that outcome was compared with a suitable control.
Gonadorelin is a preparation of gonadotropin-releasing hormone, or GnRH. Its clinical interpretation depends on the diagnosis and the pattern of administration. Evidence for a carefully selected fertility population using a pulsatile pump should not be turned into a general hormone-optimization promise.
Human growth hormone is a protein hormone; somatropin is a recombinant medicinal form. Product-specific clinical uses should be distinguished from claims that raising hormone levels rejuvenates otherwise healthy adults. Body-composition changes alone do not establish longer life, greater independence or improved athletic function.
Human relaxin-2 is a hormone studied through recombinant serelaxin preparations in cardiovascular and other disease settings. Early promising signals were not consistently confirmed in larger clinical trials. A balanced account should include that development history rather than present vascular mechanisms as proof of heart protection.
Humanin is a short peptide investigated for cellular protection in models relevant to neurodegeneration and other stresses. The selected original experiments are laboratory studies. They help identify biological questions, but do not establish that a Humanin product improves memory, treats dementia or slows aging in people.
Ibutamoren, also called MK-677, is an orally studied small-molecule growth-hormone secretagogue, not a peptide. Human trials show that it can raise growth hormone and IGF-1. They also show why a hormone increase should not be presented as proof of improved cognition, physical function or fat loss.
IGF-1 LR3 is a modified analogue of insulin-like growth factor 1, used in experimental research. Its structural changes alter interactions with binding proteins. That biochemical distinction does not establish that it safely builds muscle, repairs injuries or improves recovery in people.
Ipamorelin is a synthetic peptide studied for growth-hormone release and gastrointestinal effects. Human research exists, but the outcome matters: a hormone response is not proof of muscle gain, and a postoperative trial did not demonstrate a significant improvement in its main efficacy comparisons.
KLOW is a blend label rather than a single defined peptide. This guide concerns combinations listing KPV alongside BPC-157, a thymosin-related ingredient and GHK-Cu. The exact composition must be documented for each preparation; the name alone does not establish a standardized formula or clinical effect.
KPV is the three-amino-acid sequence Lys-Pro-Val, investigated in inflammation research. Primary studies show effects in cultured cells and mouse models of colitis. Those findings are a reason for further research, not proof that a KPV product treats inflammatory bowel disease or other human conditions.
LL-37 is a human host-defense peptide investigated in wound healing. Topical clinical findings are mixed and cannot establish the benefits of systemic administration.
Modified GRF 1-29 refers to altered growth-hormone-releasing-factor peptides. Evidence about unmodified GRF or other analogues cannot establish the effects of an unspecified vendor sequence.
NAD+ is a metabolic coenzyme. Direct NAD infusion, precursor supplementation and cellular NAD measurements are different interventions and should not share one efficacy claim.
Prostatilen appears in studies of prostate-derived polypeptide preparations. Clinical reports concern particular formulations; they do not establish that an unspecified peptide vial has the same composition or effects.
Retinalamin is a polypeptide preparation studied in retinal disease. The human reports describe selected structural and functional measurements, not a demonstrated general restoration of vision.
Elamipretide, also called SS-31, is the ingredient in Forzinity, approved for a defined Barth-syndrome population. That narrow approval does not establish general anti-aging use.
TB-500 requires exact identity checking. Analytical papers identify an acetylated seven-residue thymosin beta-4 fragment; full-length thymosin beta-4 studies do not automatically apply to that fragment.
Tesamorelin is a GHRH analogue approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for general weight-loss management.
Thymosin alpha-1 has been investigated in disease-specific clinical trials. Results differ across studies; a general immune-boosting claim obscures both the patient setting and the uncertainty.
VIP is a signaling peptide studied as a biomarker and experimental intervention. A change in natural VIP levels does not demonstrate that administering VIP treats the associated condition.
Vitamin B12, also called cobalamin, is an essential vitamin rather than a peptide. Correcting B12 deficiency is a distinct medical objective from selling an energy boost to someone with adequate B12 status. Evidence for the first does not establish the second.
Wolverine Stack is a marketing name for a peptide combination, commonly described as BPC-157 with a TB-500-related ingredient. Its composition must be established before any evidence can be evaluated.